Improving siRNA Production Efficiency

With engineered double-stranded RNA (dsRNA) ligases

Demand for oligonucleotide therapeutics, such as small interfering RNA (siRNA) and antisense oligonucleotides (ASOs), has skyrocketed as their use has expanded to encompass larger disease indications. This exciting shift in the industry creates the need for enhanced manufacturing technologies.

In this paper, we showcase how engineered double-stranded RNA (dsRNA) ligases, designed for ligation of RNA fragments as a novel synthesis approach to improve siRNA production efficiency.

Engineered dsRNA ligases can efficiently scale siRNA manufacturing through:

Faster process development
Improved manufacturability
Custom pharma manufacturing expertise
Higher scalability
Complements solid state synthesis

See how by downloading this white paper.